XORTX Adds Health Canada CTA Filing to Gout Program, Accelerating Global Regulatory Push
XRTX sits 47% above its 52-week low of $1.59 on elevated volume (12× avg).
Summary
XORTX announced plans to file a Clinical Trial Application with Health Canada for its XRx-026 gout program, adding a Canadian regulatory pathway alongside its previously disclosed FDA IND submission. The CTA supports a two-part clinical study, XRX-OXY-102, with the first part conducted in Canada to accelerate data delivery for the planned NDA filing with the FDA. This follows the September 18 announcement of the FDA IND plan and the September 10 start of GMP manufacturing for XORLO™. The company also noted increased inquiries from potential commercialization partners, though no agreements have been reached. The move broadens the regulatory strategy and could speed clinical data generation, but the company remains in a going-concern position with a $2.5 million H1 net loss.
At the time of this announcement, XRTX was trading at $2.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $1.59 to $7.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.